Olimesta (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olimesta, is an angiotensin II receptor blocker presented as a tablet for oral use. It is indicated for the management of hypertension in adults. GNH USA supplies Olimesta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olimesta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olimesta (olmesartan) is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy (adjunct): may slow progression of kidney damage when used with other antihypertensives. - Heart failure (off‑label): sometimes used to support blood‑pressure control in heart‑failure patients. - Stroke prevention (off‑label): contributes to secondary prevention strategies after ischemic stroke. - Chronic kidney disease (off‑label): assists in blood‑pressure management in CKD patients.

Adverse reactions to olmesartan are generally mild to moderate and vary among individuals.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Back pain

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Bullous skin eruptions (e.g., Stevens‑Johnson syndrome)

When using Olimesta, consider the following safety measures:

- Renal function monitoring: assess serum creatinine and eGFR before initiation and periodically thereafter. - Electrolyte assessment: check potassium levels, especially if combined with potassium‑sparing diuretics or supplements. - Pregnancy contraindication: avoid use during pregnancy, particularly in the second and ​  ​  ​  ​ ​ ​ ​  ​  ​   ​  ​       ​  ​  ​    ​     ​    ​    ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​  ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Concomitant drug review: avoid combining with other potent antihypertensives that may cause excessive blood‑pressure decline. - Patient education: advise  ​   ​    ​  ​   - Store at    ​ ​   - Store  ​ ​  

Ol